The Week in Review: Newsummit to Stage $80 Million IPO on NYSE

Newsummit Biopharma, a Shanghai preclinical CRO, filed to raise up to $80 million in an IPO on the NYSE IPO; Pfizer and Zhejiang Hisun Pharma will put $545 million of assets into their branded generics JV; Pfizer said it wants to keep pursuing “opportunities” in China and India to expand its generic drug portfolio; Fosun Pharma bought an 18% stake in SD Biosensor, a Korean company that makes in-vitro diagnostic devices; BGI will collaborate with Western Big Pharma to discover genetic causes of the most common cancers in Asia; China will raise the healthcare insurance subsidy for farmers and non-working urban residents by 80%; Hutchison MediPharma began a first-in-human Phase I clinical trial of a cancer drug, volitinib (HMPL-504) that it co-develops with AstraZeneca; Access Pharma was granted SFDA approval for its oral mucositis treatment, MuGard™; and Dynex Technologies of Virginia received SFDA approval for its automated DS2® ELISA analyzer. More details…. Stock Symbols: (NYSE: PFE) (SHA: 600267) (SHA: 600196) (NYSE: AZN) (OTCBB: ACCP) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});